Choosing Wisely:

Don’t routinely screen for prostate cancer using a prostate-specific antigen (PSA) test or digital rectal exam.

Rationale and Comments: There is convincing evidence that PSA-based screening leads to substantial overdiagnosis of prostate tumors. Many tumors will not harm patients, while the risks of treatment are significant. Physicians should not offer or order PSA screening unless they are prepared to engage in shared decision making that enables an informed choice by patients.
Sponsoring Organizations:
  • American Academy of Family Physicians
  • Sources:
  • U.S. Preventive Services Task Force
  • Disciplines:
  • Preventive Medicine
  • Oncologic
  • Urologic
  • References: • American Academy of Family Physicians. Prostate cancer [Internet]. Leawood (KS): American Academy of Family Physicians; 2012 [cited 2013 Jul 23]. Available from:
    • U.S. Preventive Services Task Force. Screening for prostate cancer. Rockville (MD): U.S. Preventive Services Task Force. 2012 May. 16 p.

    Email Alerts

    Don't miss a single issue. Sign up for the free AFP email table of contents.

    Sign Up Now